Blueprint Medicines Corporation (NASDAQ:BPMC) Files An 8-K Regulation FD Disclosure

ME Staff 8-k
-
0

Blueprint Medicines Corporation (NASDAQ:BPMC) Files An 8-K Regulation FD Disclosure
Item 7.01Regulation FD Disclosure.

On December 10, 2017, Blueprint Medicines Corporation (the “Company”) issued a press release announcing new data from its ongoing Phase 1 clinical trial evaluating avapritinib (formerly known as BLU-285) for the treatment of advanced systemic mastocytosis. The data were presented on Sunday, December 10, 2017 in an oral presentation during the plenary session at the American Society of Hematology (“ASH”) Annual Meetingin Atlanta, Georgia. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K, and a copy of the presentation at the ASH Annual Meeting is furnished as Exhibit 99.2 to this Current Report on Form 8-K.

In addition, on December 11, 2017, the Company hosted an investor conference call and live webcast to discuss the data presented at the ASH Annual Meeting and provide a corporate update. A copy of the presentation from the conference call is furnished as Exhibit 99.3 to this Current Report on Form 8-K.

The information in Item 7.01 of this Current Report on Form 8-K, including Exhibits 99.1, 99.2 and 99.3, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.

Description

99.1

Press release issued by Blueprint Medicines Corporation on December 10, 2017

99.2

Presentation by Blueprint Medicines Corporation at the ASH Annual Meeting on December 10, 2017

99.3

Presentation by Blueprint Medicines Corporation at investor conference call on December 11, 2017


Blueprint Medicines Corp Exhibit
EX-99.1 2 ex-99d1.htm EX-99.1 bpmc_Ex99_1 Exhibit 99.1   Blueprint Medicines Announces New Data from Ongoing Phase 1 Clinical Trial of Avapritinib (BLU-285) in Patients with Advanced Systemic Mastocytosis Showing Evidence of Strong Clinical Activity   – Overall Response Rate of 72 Percent and Disease Control Rate of 100 Percent Reported – – Plan to Engage Global Regulatory Authorities in First Half 2018 on Registration Pathway – – Blueprint Medicines to Host Investor Conference Call and Webcast on Monday,…
To view the full exhibit click here

About Blueprint Medicines Corporation (NASDAQ:BPMC)

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. The Company focuses on crafting drug candidates with therapeutic windows that provide clinical responses to patients without adequate treatment options. The Company has developed a small molecule drug pipeline in cancer and a genetic disease. The Company’s drug candidate, BLU-285, targets KIT Exon 17 mutants and PDGFRa D842V, which are abnormally active receptor tyrosine kinase mutants that are drivers of cancer and proliferative disorders. It is engaged in developing BLU-285 for patients with systemic mastocytosis (SM), a myeloproliferative disorder of the mast cells, and defined subsets of patients with gastrointestinal stromal tumor (GIST). Its drug candidate, BLU-554, targets FGFR4, a kinase that is aberrantly activated and is a driver of disease in a defined subset of patients with hepatocellular carcinoma (HCC).